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Abstract
Introduction This paper describes the implementation of nov-
el oral anticoagulants (NOACs) through an anticoagulation
nurse. Logistics and tasks of this new function are described
and preliminary data are presented.
Methods Indications for NOACs are explained by the treating
cardiologists. Thereafter, the patient is referred to the
anticoagulation nurse before starting a NOAC. After provid-
ing a patient with information and checking the creatinine
clearance, co-medication and medical history, a prescription
for NOAC is made.
Results In 3 months, 51 patients were referred for NOAC
therapy. Mean age was 68 years, CHA2DS2-VASc score
was 2.9. Renal function was impaired in 28 %. Only 63 %
of the patients had an uneventful start-up. NOAC therapy was
withheld or prematurely stopped in 22 %. 30 % of patients
needed a reduced NOAC dose. In 37 %, the anticoagulation
nurse had extended patient contact, mainly because of
(presumed) side effects.
Conclusion Given the number of interactions that were made
using a separate patient contact through the anticoagulation
nurse, this seems to be an important improvement in the
quality of care and deserves further expansion.
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Introduction
European guidelines state a preference for novel oral antico-
agulants (NOACs) above vitamin K antagonists (VKA) for
the indication non-valvular atrial fibrillation (AF) [1, 2]. In the
Netherlands, the Ministry of Health ordered measures to be
taken for the safe prescription of these drugs by professionals,
which led to the Guideline for the introduction of new oral
anticoagulants, known as the Leidraad [3]. This paper de-
scribes the implementation of the ‘Leidraad’ in The Medical
Centre Leeuwarden, thereby creating a new function for the
anticoagulation nurse. Preliminary data are presented of our
first experience with NOACs using this format.
Methods
The anticoagulation nurse
In order to secure ‘chain care’, a new function of the
anticoagulation nurse was launched in close collaboration
with the Thrombosis Service, Department of Internal
Medicine and the Hospital Pharmacy.
During an outpatient visit, indications for using anticoagu-
lants are explained by the treating cardiologists but a profound
discussion over the benefits and disadvantages of using a
NOAC is usually lacking. Therefore, in our hospital, the
patient is referred to the anticoagulation nurse before starting
a NOAC.
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After providing a patient with information and
checking the creatinine clearance, co-medication and
medical history, a prescription for NOAC and authori-
sation form for the health insurance company is pro-
duced. A supervising cardiologist controls the checklist
and signs the prescription and authorisation form. A
standard letter mentions the indication, drug and dose,
comorbidity, creatinine clearance, other drugs and the
CHA2DS2-VASc and HASBLED scores.
Data regarding compliance, side effects, and compli-
cations are marked in a central database. A major ad-
vantage of the anticoagulation nurse is that all patients
potentially receiving a NOAC are identified centrally. In
this way, the NOAC prescriber, in this case the cardi-
ologist, is able to take adequate control over this new
therapy.
Results
The anticoagulation nurse started in February 2013. After
3 months, 51 patients have been referred for NOAC therapy;
mean age was 68 years, 65 % males (Table 1).
After consultation with the anticoagulation nurse, in
8/51 patients (16 %) no NOAC was prescribed: two
patients were considered to lack an indication for oral
anticoagulation, because of lack of registration of AF
and left atrial appendix amputation during prior cardiac
surgery, respectively. Three patients refused NOAC be-
cause of negative publicity. In another three patients,
NOAC therapy was contraindicated because of concom-
itant severe gastrointestinal (including stomach) symp-
toms or poor renal function. Of the 43 patients who
started on a NOAC, 13 (30 %) were treated with a
reduced dose, mainly because of abnormal renal func-
tion, defined as eGFR ≤50 ml/min.
The anticoagulation nurse had additional contacts with 11
of 43 patients (26 %). In three patients, NOAC therapy was
stopped within 2 weeks because of side effects. One patient
developed rash, itch and oedema. One patient suffered from
fatigue and one patient had a minor bleed, and refused further
NOAC therapy because of lack of an antidote. Four had minor
bleeding and one bridging advice was given. In three patients,
possible side effects were reported, but drug continuation was
advised. Figure 1 shows the flowchart of patients during the
study.
In conclusion, after referral, 32/51 (63 %) of the
patients had an uneventful start-up of NOAC therapy.
NOAC therapy was withheld or prematurely stopped in
22 %. A considerable number of patients needed a
reduced NOAC dose. In 37 %, the coagulation nurse
had extended patient contact, mainly because of
(presumed) side effects.
Discussion
This pilot study describes the logistics and first experi-
ence of a new function of anticoagulation nurse.
Although a central role for pharmacists has been pro-
posed by ‘De Leidraad’, in our model cardiologists are
comprehensively facilitated in keeping control over
NOAC therapy. In this way they can fully comply with
their role as prescriber of anticoagulation.
The main finding of our observations is that an
anticoagulation nurse is a feasible and valuable interme-
diate between the cardiologist and the patient. These
data suggest that introducing a NOAC is labour inten-
sive and an additional patient contact is pivotal for
safety and education. The anticoagulant nurse is easily
Table 1 Baseline characteristics
Characteristics N=51 (%)
Age, year 68
Male, n (%) 33 (65)
eGRF ≥60 ml/min 37 (73)
- 50–60 ml/min 6 (12)
- <50 ml/min 8 (16)
CHA2DS2-VASc score 2.9
HASBLED score 1.9
VKA naive 20 (39)
Switch from VKA 31 (61)
Main reason for switching to NOAC
- User friendly 4/31 (13)
- Dislike frequent blood sample taking 6 (19)
- Side effects 2 (6)
- Cardiologist’s advice 4 (13)
- Labile INR (according to patient) 4 (13)
- After use in trial 1 (3)
- Unknown or no specific reason 10 (32)
Dabigatran dose
- 2 dd 150 mg 8 (18)*
- 2 dd 110 mg 9 (20)*
Rivaroxaban dose
- 1 dd 20 mg 22 (51)*
- 1 dd 15 mg 4 (9)*
Reason reduced NOAC dose
- Reduced creatinine clearance 8 (62)
- Age, years 2 (15)
- Drug interaction 2 (15)
- Around PVI 1 (8)
*Referred to 43 patients, n=43, after exclusion of 8 patients who were not
prescribed with an NOAC
NOAC novel oral anticoagulants; PVI pulmonary vein isolation; VKA
vitamin K antagonists
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accessible for patients and helps with additional tasks
such as registration of complications. [4].
Recently, the Ministry of Health has strongly encouraged
the use of a case manager for oral anticoagulants [4]. The
function of the anticoagulation nurse can be extended to a case
manager for all patients using oral anticoagulants.
Safety of NOAC’s: research versus daily practice
The most important requirement before starting prescribing a
NOAC is the organisation of ‘chain care’ [3–5]. During a
randomised clinical trial (RCT), this is done by the research
institute and dictated by a strict protocol. Frequent contacts
and patient education may bias towards more safety in RCTs.
A run-in phase of a trial usually excludes non-compliant
patients as well as patients prone to side effects. The
anticoagulation nurse helps to prevent prescription errors
which is an important determinant of iatrogenic bleeding [6].
In our small cohort, it was decided to withhold a NOAC in 8
patients after extended discussion. We believe, especially in
the introduction phase, that intensive consideration of the
indication for a NOAC is necessary to preclude prescription
to the ‘frail elderly’ as well as potentially non-compliant
patients.
Major vs minor bleeding
Compared with stroke and major bleeding, patients much
more frequently suffer from minor side effects, such as minor
bleeding or dyspepsia. Every year, minor bleeding may occur
in 1 out of 6–7 patients. Within 2 years, 1 out of 4–5 patients
will discontinue NOAC therapy [7–9]. In these patients, a
transoesophageal echocardiography-guided strategy may be
useful since it may help to avoid anticoagulation in apparently
low-risk patients with non-valvular AF [10].
Our data suggest that after prescribing a NOAC, it is
expected that caregivers will have contact with the patient
much more often than anticipated. The Thrombosis Service
represents a robust network and takes care of questions from
patients on VKA. However, for NOACs, no safety network
exists in this respect, bouncing all drug-related questions back
to the prescriber. Therefore, the anticoagulation nurse will
pick up all items regarding the NOAC resulting in a solid
chain care to fill up this gap in our hospital.
51 patients referred for NOAC
after anticoagulation consultation
43 patients were prescribed NOAC 8 no NOAC prescribed
- 2 no indication
- 2 relative contraindication 
because of gastrointestinal symptoms 
- 3 refused after information and
negative publicity in media
- 1 poor renal function, frail elderly patient
3 patients stopped after side effects
- 1 minor bleeding, stopped after 2 weeks on own request, nervousness 
- 2 side effects: rash, itch, oedema, fatigue 
40 continued use
32 uneventful use 8 additional contact because of minor side effects
- 4 small haematoma
- 1 perioperative advice 
- 3 possible side effects but continuation of chronic use
1 headache, muscular pain, fatigue
1 gastric pain treated with pantoprazol
1 dry and itchy eyes
Fig. 1 Flowchart of patients
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Limitations
From our observational data in this first cohort with short
follow-up we cannot tell whether complex anticoagulation care
pivoting around an anticoagulation nurse improves
anticoagulation care and is cost-effective. However, consider-
ing the intensive early follow-up contacts of the anticoagulation
nurse with the patients, leading to essential changes in therapy,
this new example of ‘chain care’ seems to serve its goal. To
support this notion, we can proudly state that thus far no major
bleeding or stroke has occurred. At present we do not have data
on quality of life but this maywell improve through our service.
Considering our experience up to now it seems advisable to
install and expand anticoagulation care with the anticoagulation
nurse as a pivot point.
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